Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.

  title={Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter.},
  author={Bramahn . Singh and Stuart J. Connolly and Harry J.G.M. Crijns and Denis Roy and Peter Russell Kowey and Alessandro Capucci and David Radzik and Etienne M. Aliot and Stefan H. Hohnloser},
  journal={The New England journal of medicine},
  volume={357 10},
BACKGROUND Amiodarone is effective in maintaining sinus rhythm in atrial fibrillation but is associated with potentially serious toxic effects. Dronedarone is a new antiarrhythmic agent pharmacologically related to amiodarone but developed to reduce the risk of side effects. METHODS In two identical multicenter, double-blind, randomized trials, one conducted in Europe (ClinicalTrials.gov number, NCT00259428 [ClinicalTrials.gov] ) and one conducted in the United States, Canada, Australia… 

Figures and Tables from this paper

Dronedarone Therapy in Atrial Fibrillation: A Summary of Recent Controlled Trials

A large randomized study in more than 4600 patients with nonpermanent AF, which used the primary end point of time to first cardiovascular (CV) hospitalization or death, significantly reduced the incidence of the primary as well as several secondary end points among which CV mortality was the most significant one.

Usefulness of dronedarone in patients with atrial arrhythmias.

Effect of dronedarone on cardiovascular events in atrial fibrillation.

Dronedarone reduced the incidence of hospitalization due to cardiovascular events or death in patients with atrial fibrillation and had higher rates of bradycardia, QT-interval prolongation, nausea, diarrhea, rash and an increased serum creatinine level than the placebo group.

Benefit-Risk Assessment of Dronedarone in the Treatment of Atrial Fibrillation

Compared with amiodarone, dronedarone has fewer toxic effects and, although less efficacious, may be used as first-line therapy for maintenance of sinus rhythm in patients with non-permanent AF.

Dronedarone: A New Antiarrhythmic Agent for the Treatment of Atrial Fibrillation

Dronedarone is likely to be a useful addition to the therapeutic management of AF and further comparative studies with amiodarone are needed to define dron Cedarone's place in therapy more clearly.

Safety and Efficacy of Dronedarone in the Treatment of Atrial Fibrillation/Flutter

Dronedarone is an amiodarone analog but differs structurally from amiodarone in that the iodine moiety was removed and a methane-sulfonyl group was added. These modifications reduced thyroid and

Dronedarone New

Evidence of safety and effectiveness of dronedarone reduces mortality and morbidity in patients with high-risk atrial fibrillation, but may be unsafe in those with severe heart failure.

Dronedarone for the treatment of non-permanent atrial fibrillation: National Institute for Health and Clinical Excellence guidance

The marketing authorisation for dronedarone followed an extensive development programme involving six trials that enrolled over 7000 patients, and it was found that the smallest dose tested was the most suitable dose for the suppression of AF recurrence.



Dronedarone: An Amiodarone Analog for the Treatment of Atrial Fibrillation and Atrial Flutter

Dronedarone is a new antiarrhythmic agent for the treatment of atrial fibrillation and further studies are needed to better define dron Cedarone's safety profile and place in therapy.

Increased mortality after dronedarone therapy for severe heart failure.

In patients with severe heart failure and left ventricular systolic dysfunction, treatment with dronedarone was associated with increased early mortality related to the worsening of heart failure.

Amiodarone versus sotalol for atrial fibrillation.

Amiodarone-associated Proarrhythmic Effects: A Review with Special Reference to Torsade de Pointes Tachycardia

The proarrhythmic potential of amiodarone is examined, with particular reference to its ability to provoke polymorphic ventricular tachycardia of the torsade de pointes type.

New approaches to atrial fibrillation management: a critical review of a rapidly evolving field.

Significant advances are being made in the management of patients with AF but much more work remains to be done.

A comparison of rate control and rhythm control in patients with atrial fibrillation.

Management of atrial fibrillation with the rhythm-control strategy offers no survival advantage over the rate- control strategy, and there are potential advantages, such as a lower risk of adverse drug effects, with the rate -control strategy.

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

Quinidine treatment is more effective than no antiarrhythmic therapy in suppressing recurrences of atrial fibrillation but appears to be associated with increased total mortality.